Big Data and Genomic Imaging for the Development of Biomarkers and Nanovector Drugs Innovative for Diagnosis and Therapy of Inflammatory Processes in Dementia

CompletedOBSERVATIONAL
Enrollment

137

Participants

Timeline

Start Date

June 17, 2020

Primary Completion Date

February 28, 2023

Study Completion Date

June 30, 2023

Conditions
Neurodegenerative Diseases
Interventions
RADIATION

Magnetic Resonance (MR) and positron emission tomograph (PET) imaging analyses

"Regarding the neurological MR protocol, the following may be acquired:~* 3D T1 and T2 high-resolution sequences, acquired in a specific plane and Multiplanar reformation (MPR) reconstructed in the remaining orthogonal planes, for morphological assessment of the different structures under examination;~* diffusion sequences for the evaluation of the connection between different areas within a specific organ;~* perfusion sequences (ASL, arterial spin labeling) for the evaluation of perfusion without ev mdc administration;~* susceptibility sequences for noninvasive assessment of vasculature and deposits of iron."

Trial Locations (1)

80143

IRCCS Synlab SDN, Naples

All Listed Sponsors
lead

IRCCS SYNLAB SDN

OTHER

NCT05761535 - Big Data and Genomic Imaging for the Development of Biomarkers and Nanovector Drugs Innovative for Diagnosis and Therapy of Inflammatory Processes in Dementia | Biotech Hunter | Biotech Hunter